Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules SASKATOON, SK, Aug. 26, 2025 /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l'Université de Montréal ("CHUM") as first clinical site in its Phase 2a UTOPIA-1 (U ...

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcoming investor conferences in September 2025 as follows: Cantor Healthcare Conference: fireside chat at 8:00 am ET on Thursday, September 4th and available to host inve ...

Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services to the life ...

Core Viewpoint - Eli Lilly's daily weight loss pill, orforglipron, has shown significant efficacy in helping patients with obesity and Type 2 diabetes lose weight in a late-stage trial, paving the way for global approval filings [1][5]. Group 1: Drug Efficacy and Trial Results - The highest dose of orforglipron resulted in an average weight loss of 10.5%, or 22.9 pounds, over 72 weeks, compared to a 2.2% weight loss in the placebo group [3]. - The drug also effectively lowered hemoglobin A1c levels, with most patients no longer meeting the criteria for Type 2 diabetes by the end of the study [4]. - The overall weight loss across all patients was 9.6%, regardless of discontinuations [3]. Group 2: Market Position and Competitive Advantage - Orforglipron is positioned as a needle-free alternative in the lucrative GLP-1 market, potentially increasing accessibility compared to existing weekly injections [2]. - The pill does not impose dietary restrictions, unlike a similar oral treatment from Novo Nordisk, enhancing its appeal [2]. Group 3: Side Effects and Patient Experience - The side effects were primarily gastrointestinal, with 23.1% experiencing vomiting and 36.4% and 27.4% reporting nausea and diarrhea, respectively [9]. - Approximately 20% of patients discontinued the pill for various reasons, similar to the placebo group, indicating a mix of factors beyond side effects [10]. Group 4: Future Outlook and Market Potential - Eli Lilly expects to launch the pill globally around this time next year, having gathered the necessary clinical trial data for regulatory approvals [5]. - The potential market is substantial, with over 100 million adults in the U.S. affected by obesity, highlighting the opportunity for orforglipron [11]. - Analysts suggest that the pill's easier manufacturing process and lack of dietary restrictions could make it a viable competitor in the obesity treatment space [15].

Core Insights - Eli Lilly announced positive topline results from the Phase 3 ATTAIN-2 trial for orforglipron, an investigational oral GLP-1 receptor agonist, showing significant weight loss and A1C reductions in adults with obesity or overweight and type 2 diabetes [1][2][4] Efficacy Results - Orforglipron 36 mg led to an average weight loss of 22.9 lbs (10.5%) and a reduction in A1C by 1.8% after 72 weeks, compared to 5.1 lbs (2.2%) weight loss and 0.1% A1C reduction in the placebo group [1][2] - In the trial, 75% of participants on the highest dose achieved an A1C ≤6.5%, meeting the American Diabetes Association's definition of diabetes [2][4] - The trial demonstrated that orforglipron met all primary and key secondary endpoints, including significant improvements in cardiometabolic risk factors [1][4] Safety Profile - The safety profile of orforglipron was consistent with established GLP-1 receptor agonists, with the most common adverse events being gastrointestinal-related, such as nausea (20.1% to 36.4%), vomiting (12.8% to 23.1%), and diarrhea (21.3% to 27.4%) across different doses [4][8] - Treatment discontinuation rates due to adverse events were 6.1% for 6 mg, 10.6% for 12 mg, and 10.6% for 36 mg, compared to 4.6% for placebo, indicating a balanced overall treatment discontinuation rate [4][8] Regulatory Pathway - With the completion of the ATTAIN-2 trial, Eli Lilly is prepared to initiate global regulatory submissions for orforglipron, aiming to provide a convenient, once-daily oral treatment option for obesity and type 2 diabetes [1][4][6] Clinical Trial Details - The ATTAIN-2 trial was a 72-week, randomized, double-blind, placebo-controlled study involving over 1,600 participants across multiple countries, focusing on the efficacy and safety of orforglipron [7][8]

Group 1 - Pfizer's stock is currently facing a significant credibility discount due to the near-total loss of its $5.4 billion acquisition of Global Blood Therapeutics in 2022 [1] - The failure of this acquisition has contributed to the negative perception of Pfizer in the stock market [1] Group 2 - The article highlights the importance of a comprehensive and fundamental approach to investment analysis, emphasizing the need to identify hidden gems in the market [1]

Group 1 - Noan Fund recently conducted research on six listed companies, focusing on their growth strategies and market opportunities [1] - StarNet Ruijie is emphasizing optical communication in the telecommunications sector, with significant revenue growth expected from its collaboration with domestic operators [1] - Ruijie Network's data center product revenue is primarily driven by internet clients, with a notable increase in overseas business revenue [1] - Baile Tianheng is advancing multiple clinical trials for cancer treatments and aims to become a leading player in oncology within five years [2] - Stanley achieved steady growth in revenue and profit, driven by improved product structure and effective pricing strategies in the compound fertilizer sector [2] Group 2 - Chip Origin is providing customized hardware and software solutions in the AI field, with a high percentage of R&D personnel and a focus on enhancing chip customization capabilities [3] - Cambridge Technology is expanding its production capacity for 800G series products, with plans for further expansion supported by self-funding and potential financing [4]

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Novo Nordisk made misleading statements about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded products [2]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, as well as competition and market expansion issues [2]. - Following this announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Legal Proceedings - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Novo Nordisk, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiffs must file a motion with the Court by September 30, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Novo Nordisk provided misleading statements about its growth potential while concealing material adverse facts [4] - It is claimed that the company overstated its potential in the GLP-1 market and the likelihood of patients switching to its branded alternatives, leading to investor damages when the truth was revealed [4]

SOUTH SAN FRANCISCO, Calif and VANCOUVER, BC, Aug. 25, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the Company's previously announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Comp ...